Journal of South Asian Federation of Obstetrics and Gynaecology

Register      Login

VOLUME 13 , ISSUE 6 ( November-December, 2021 ) > List of Articles

Original Article

Role of Sildenafil Citrate Therapy in Early-onset Fetal Growth Restriction

Rashmi Yadav, Amitesh Yadav, Alka Kumari

Keywords : Amniotic fluid index (AFI), Effective fetal weight (EFW), Fetal growth restriction (FGR), Sildenafil citrate

Citation Information : Yadav R, Yadav A, Kumari A. Role of Sildenafil Citrate Therapy in Early-onset Fetal Growth Restriction. J South Asian Feder Obs Gynae 2021; 13 (6):392-395.

DOI: 10.5005/jp-journals-10006-1976

License: CC BY-NC 4.0

Published Online: 04-03-2022

Copyright Statement:  Copyright © 2021; The Author(s).


Abstract

Objective: Fetal growth restriction (FGR) refers to a condition in which a fetus is unable to achieve its genetically determined potential size. The common consequences of FGR are neonatal mortality and neurological and neurodevelopmental delays. In this study, we investigated the use of sildenafil citrate therapy in the management of early-onset FGR. Methods: In this prospective randomized controlled study, women aged 20–35 years with singleton pregnancy with 22–32 weeks gestation age, who were having abdominal circumference (AC) less than the 10th percentile, effective fetal weight (EFW) less than the 10th percentile, or amniotic fluid index (AFI) less than or equal to 7 cm were enrolled in the study after obtaining written informed consent. These patients were randomized according to a computer-generated random numbers table and were divided into two groups, namely, group A and group B. Group A women were treated with sildenafil citrate 25 mg per oral three times daily until delivery. Group B women were not treated with sildenafil. Results: On follow-up, the abdominal circumference growth was significantly higher in group A (p = 0.0001) than in group B. Enrollment to delivery duration was average 64.85 ± 13.86 days in group A and 55.35 ± 16.18 days in group B, which is statistically significant (p = 0.0001). Mean birth weight of babies was 2040.92 ± 478.73 g in group A and 1665.60 ± 464.74 g in group (p = 0.007). Conclusion: Sildenafil therapy 25 mg twice a day from the diagnosis of FGR to delivery was beneficial to pregnant women in terms of increase in fetal AC, fetal weight, and pregnancy duration. Clinical significance: Sildenafil therapy 25 mg twice a day from the diagnosis of FGR to delivery was beneficial to pregnant women with FGR in terms of increase in fetal AC, fetal weight, AFI, and pregnancy duration (gain in intrauterine life).


HTML PDF Share
  1. Arias F, Bhide AG, Arulkumaran S, et al. Arias’ practical guide to high-risk pregnancy and delivery—e-book: A South Asian perspective. Elsevier Health Sciences 2015 Jan. p 416.
  2. Gordijn SJ, Beune IM, Thilaganathan B, et al. Consensus definition of fetal growth restriction: A Delphi procedure. Ultrasound Obstet Gynecol 2016;48:333–339. DOI: 10.1002/uog.15884.
  3. Khalil A, Morales-Rosello J, Townsend R, et al. Value of third-trimester cerebroplacental ratio and uterine artery Doppler indices as predictors of stillbirth and perinatal loss. Ultrasound Obstet Gynecol 2016;47:74–80. DOI: 10.1002/uog.15729.
  4. DeVore GR. The importance of the cerebroplacental ratio in the evaluation of fetal well-being in SGA and AGA fetuses. Am J Obstet Gynecol 2015;213:5–15. DOI: 10.1016/j.ajog.2015.05.024.
  5. MacDonald TM, Hui L, Tong S, et al. Reduced growth velocity across the third trimester is associated with placental insufficiency in fetuses born at a normal birthweight: A prospective cohort study. BMC Med 2017;15:164. DOI: 10.1186/s12916-017-0928-z.
  6. Sharma D, Farahbakhsh N, Shastri S, et al. Intrauterine growth restriction: Part 2. J Matern Fetal Neonatal Med 2016;29: 4037–4048. DOI: 10.3109/14767058.2016.1154525.
  7. Katanoda K, Noda M, Goto A, et al. Impact of birth weight on adult-onset diabetes mellitus in relation to current body mass index: The Japan nurses’ health study. J Epidemiol 2017;27:428–434. DOI: 10.1016/j.je.2016.08.016.
  8. Lindstrom L, Wikstrom AK, Bergman E, et al. Born small for gestational age and poor school performance: How small is too small? Horm Res Paediatr 2017;88: 215–223. DOI: 10.1159/000477905.
  9. Lee AC, Kozuki N, Cousens S, et al. Estimates of burden and consequences of infants born small for gestational age in low and middle income countries with intergrowth-21st standard: Analysis of CHERG datasets. BMJ 2017;358:j3677. DOI: 10.1136/bmj.j3677.
  10. Von Dadelszen P, Dwinnell S, Magee LA, et al. Sildenafil citrate therapy for severe early-onset intrauterine growth restriction. BJOG 2011 Apr;118(5):624–628. DOI: 10.1111/j.1471-0528.2010.02879.x.
  11. Kubo M, Umekawa T, Maekawa Y, et al. Retrospective study of tadalafil for fetal growth restriction: Impact on maternal and perinatal outcomes. J Obstet Gynaecol Res 2017;43(2):291–297. DOI: 10.1111/jog.13218.
  12. Mohammed EE, Alashkar OS, Abdeldayem TM, et al. The use of low dose sildenafil citrate in cases of intrauterine growth restriction. Clin Obstet, Gynecol Reprod Med 2017;3(4). DOI: 10.15761/COGRM.1000192.
  13. Premalatha HL, Raghupathi KM, Srinivas DN, et al. Study of effect of sildenafil citrate in pregnant women with intrauterine growth restriction/oligohydramnios. Int J Reprod, Contr, Obstet Gynecology 2017 Feb;5(9):3094–3097. DOI: 10.18203/2320-1770.ijrcog20162992.
  14. Choudhary R, Desai K, Parekh H, et al. Sildenafil citrate for the management of fetal growth restriction and oligohydramnios. Int J Women's Health 2016;8:367–372. DOI: 10.2147/IJWH.S108370.
  15. Maher MA, Sayyed TM, Elkhouly N. Sildenafil citrate therapy for oligohydramnios: A randomized controlled trial. Obstet Gynecol 2017 Apr;129(4):615–620. DOI: 10.1097/AOG.0000000000001928.
  16. Ferreira E, Léveillée D, Iglesias MH, et al. O-OBS-MFM-PhD-065 Sildenafil use during pregnancy for intrauterine growth restriction: A case series. J Obstet Gynaecol Canada 2016;38:486. Available from: https://doi.org/10.1016/j.jogc.2016.04.022.
PDF Share
PDF Share

© Jaypee Brothers Medical Publishers (P) LTD.